Tocilizumab in Uveitic Macular Edema Refractory to Previous Immunomodulatory Treatmentt
Tocilizumab in Uveitic Macular Edema Refractory to Previous Immunomodulatory Treatmentt
复制标题
DOI：
10.3109/09273948.2015.1099680
复制
发表时间：
2017-04-01
影响因子：
3.3
通讯作者：
Doycheva, Deshka
中科院分区：
文献类型：
--
作者：
Deuter, Christoph M. E.;Zierhut, Manfred;Doycheva, Deshka
目的：分析托珠单抗治疗对多种免疫调节药物耐药的葡萄膜炎性黄斑水肿（ME）的疗效。结果：5例（8眼）葡萄膜炎性黄斑水肿患者接受全身性泼尼松龙、至少一种免疫抑制剂和至少一种生物制剂治疗无效。3个月时，在5例患者的6只眼（75.0%）中观察到ME的反应（CFT降低>= 25%）。随访期间，4例患者的5只眼（62.5%）ME完全消退。3例3眼BCVA提高，3例3眼BCVA稳定。托珠单抗耐受性良好，没有严重的副作用occurrency.Conclusions：治疗与托珠单抗可以考虑在慢性葡萄膜炎性黄斑水肿，即使以前的免疫调节治疗失败。
Purpose: To analyze the efficacy of tocilizumab in uveitic macular edema (ME) resistant to various immunomodulatory drugs.Methods: Patients received tocilizumab every 4 weeks intravenously. Central foveal thickness (CFT) was assessed by optical coherence tomography (OCT).Results: Five patients (8 eyes) who were ineffectively pretreated with systemic prednisolone, at least one immunosuppressive drug, and at least one biologic drug for uveitic macular edema were included in the study. At 3 months, a response of ME (>= 25% reduction in CFT) was observed in 6 eyes (75.0%) of 5 patients. During follow-up, complete resolution of ME was achieved in 5 eyes (62.5%) of 4 patients. Improvement of BCVA was observed in 3 eyes of 3 patients, and stabilization in 3 eyes of 3 patients. Tocilizumab was well tolerated, and no severe side effects occurred.Conclusions: Treatment with tocilizumab can be considered in chronic uveitic macular edema even if previous immunomodulatory therapy has failed.